Roquefort Therapeutics (LON:ROQ) Stock Price Down 10.5% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ) shares were down 10.5% during mid-day trading on Wednesday . The stock traded as low as GBX 1.70 ($0.02) and last traded at GBX 1.70 ($0.02). Approximately 19,641,881 shares were traded during trading, an increase of 447% from the average daily volume of 3,591,296 shares. The stock had previously closed at GBX 1.90 ($0.02).

Roquefort Therapeutics Trading Up 0.2 %

The stock has a market cap of £2.14 million, a price-to-earnings ratio of -1.39 and a beta of 0.05. The business’s fifty day simple moving average is GBX 2.46 and its 200 day simple moving average is GBX 3.49. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07.

Insider Activity

In related news, insider Stephen Paul West acquired 400,000 shares of Roquefort Therapeutics stock in a transaction that occurred on Tuesday, February 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,535.99). Company insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.